[
  {
    "ts": "2025-08-29T21:00:28+00:00",
    "headline": "FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment",
    "summary": "Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.",
    "url": "https://www.investors.com/news/technology/biogen-eisai-under-the-skin-subcutaneous-leqembi-alzheimers-treatment/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8eff81cc-1a90-36c4-912a-89ad4f42613e",
      "content": {
        "id": "8eff81cc-1a90-36c4-912a-89ad4f42613e",
        "contentType": "STORY",
        "title": "FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment",
        "description": "",
        "summary": "Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.",
        "pubDate": "2025-08-29T21:00:28Z",
        "displayTime": "2025-08-29T21:00:28Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8eff81cc-1a90-36c4-912a-89ad4f42613e/fda-approves-biogen-eisai-s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9412ff55f8137e25eeecaa7e447fd2ad",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0rjSB4iVBdxnm0pd_Ygvuw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9412ff55f8137e25eeecaa7e447fd2ad.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5K.5wWMXidlIQp39ld5VvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9412ff55f8137e25eeecaa7e447fd2ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/biogen-eisai-under-the-skin-subcutaneous-leqembi-alzheimers-treatment/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "ESALF"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-29T21:00:00+00:00",
    "headline": "FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
    "url": "https://finance.yahoo.com/news/fda-approves-leqembi-iqlik-lecanemab-210000762.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "731fd3a5-4e74-3608-b624-1702db2d80fd",
      "content": {
        "id": "731fd3a5-4e74-3608-b624-1702db2d80fd",
        "contentType": "STORY",
        "title": "FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced \"I Click\") for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Ei",
        "pubDate": "2025-08-29T21:00:00Z",
        "displayTime": "2025-08-29T21:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bJrlns2nzwpK84mfnZzsTg--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lpiHqXXYlwJmL4_lRc2Yvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-leqembi-iqlik-lecanemab-210000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-leqembi-iqlik-lecanemab-210000762.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "ESALF"
            },
            {
              "symbol": "4523.T"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]